The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

Abstract Background Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesize...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, Zen-Kong Dai, Wei-Yu Chen, Yun-Fang Chen, An-Sheng Lee
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2019-04-01
Colecção:Cardiovascular Diabetology
Assuntos:
SGLT2 inhibitor
Empagliflozin
Hypertensive
Heart failure
Cardiac fibrosis
Hemodynamics
Acesso em linha:http://link.springer.com/article/10.1186/s12933-019-0849-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados